Navigation Links
Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models

    - Peregrine's Selective Anti-VEGF Antibodies Inhibited Tumor Growth By

                     90% In a Preclinical Cancer Model -

- Peregrine's Antibodies that Selectively Inhibit VEGF Receptor 2 Could

Potentially Have Advantages over Non-Selective Approaches -

- These Results Along with Data Presented on a Fully Human Antibody Support

Advancing Peregrine's Anti-VEGF Program towards Clinical Trials -

LOS ANGELES and TUSTIN, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer. In this model, treatment with 2C3 reduced the growth of pancreatic tumors by 90%. The researchers also assessed the anti-tumor activity of 2C3 and the marketed anti-cancer agent Avastin(R) in a number of preclinical cancer models. The anti-tumor activity of 2C3, which only blocks VEGF receptor 2 (VEGFR2) compared favorably to that of Avastin, which blocks VEGF binding to both VEGF receptor 1 (VEGFR1) and VEGFR2.

VEGF is a primary stimulant of the development and maintenance of the blood vessels needed by tumors to survive and grow. It is thought to work by binding to and activating two receptors that are expressed on endothelial and other types of cells. The series of studies reported today tested the hypothesis that selectively inhibiting VEGFR2 is an equally effective anti-tumor strategy to blocking both receptors. Most of t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:11/26/2014)... N.C. , Nov. 25, 2014  At the ... Antonio this October, KaVo Kerr Group was ... Technology Expo, offering attendees the opportunity to see and ... well-respected key opinion leaders deliver lectures on the latest ... Group products include the new DEXIS CariVu Caries Detection ...
(Date:11/26/2014)... 2014  Medtronic,s roughly $43 billion acquisition ... discussed in the media for its US Federal ... leading player in one of the fastest growing ... market research firm said  the two companies compete ... set of solutions spanning inpatient to home care, ...
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: ... injectable drug delivery systems, today announced that its Chairman ... present at the Piper Jaffray 26th Annual Healthcare Conference ... EST on Tuesday, December 2, 2014. ... as a "live" listen only Webcast. To listen, please ...
Breaking Medicine Technology:KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2
(Date:11/27/2014)... Dallas, TX (PRWEB) November 28, 2014 ... current state of the global Bronchoscopes industry with a ... statistics on the market status of the Bronchoscopes manufacturers ... for companies and individuals interested in the industry. , ... industry including its definition, applications and manufacturing technology. Then, ...
(Date:11/27/2014)... Turks and Caicos Islands; BWI (PRWEB) November 28, 2014 ... for the Tuscany Resort in the Turks & Caicos. ... resorts by TripAdvisor in Providenciales, is announcing a few ... three bedroom villa rentals. And they are offering ... resort. , Additionally, The Tuscany, is having a ...
(Date:11/27/2014)... 28, 2014 Let the Black Friday sales ... with bows on top, filled with skincare goodies, will delight ... discounted today while quantities last - no coupon required. ... are also available on Amazon at the same sales prices. ... shop product page for ease. , The company published a ...
(Date:11/27/2014)... According to a recent report by iData ... into the surgical robotics market may find ... MIS field dominated by Intuitive. These companies are expected ... market by 2020. , “The MIS robotic device ... and President of iData. “System sales for the da ...
(Date:11/27/2014)... Cambrionix Ltd today announced that it ranked ... ranking of the 50 fastest-growing technology companies in the UK. ... last five years. Cambrionix Ltd grew 2989 percent during ... the region of Cambridgeshire and East and first in the ... award is recognition of the hard work put in by ...
Breaking Medicine News(10 mins):Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:Big Christmas Sales Begin Today at Sublime Beauty® for all Christmas Gift Selections and Skincare Sets 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4
... CAWhen cells find themselves in a tight spot, the ... cells time to repair the damage, or if all ... to other stress-induced genes, which dispense with the regular ... factor that also helps with the editing of transcripts, ...
... Loyola University Health System study includes some unexpected ... Contrary to expectations, patients who died from their ... than patients who survived., "Perhaps a better understanding ... for therapies that further improve outcomes in burn ...
... CAWhen cells find themselves in a tight spot, the ... cells time to repair the damage, or if all ... to other stress-induced genes, which dispense with the regular ... factor that also helps with the editing of transcripts, ...
... children and adolescents. In the current issue of ... 173-79), Susanne Walitza and her colleagues point out that ... course of the disease. Compulsive washing, the most ... in up to 87% of all patients; other common ...
... The United States should pay close attention to how the ... worth using factors that go beyond clinical and cost effectiveness, ... Bioethics. In a commentary to appear in the April ... , the bioethicists detail and discuss a new, "value-based pricing" ...
... establishes a unique system to perform in vivo ... networks that regulate hepatocyte proliferation during chronic liver ... that stable knockdown of the candidate gene by ... of mouse hepatocytes and also increase the regenerative ...
Cached Medicine News:Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 2Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 3Health News:Surprising finding from smoke inhalation study 2Health News:‘SKIP’-ing splicing forces tumor cells to undergo programmed cell death 2Health News:‘SKIP’-ing splicing forces tumor cells to undergo programmed cell death 3Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 3
Direct gonioscopy lens with magnification. The lens rests on the scleral flange creating a corneal vault and leaving the anterior chamber angle undisturbed. Three sizes available....
West lachrymal cannula, blunt tip with inner side opening, gently curved shaft....
Lachrymal cannula, straight....
Solo-care is a multi-purpose solution for cleaning, rinsing, disinfection and storing soft contact lenses....
Medicine Products: